Article Text

Download PDFPDF
AB0550 Experience on Influenza and/ or Pneumococcal Vaccination Among Filipino Patients with SLE in a Tertiary Care Hospital
  1. A.T.S. Hernandez,
  2. M.L. Tee,
  3. A.D. Corpuz,
  4. J.L. Hipe,
  5. K.D. Tee
  1. Department of Medicine, University of the Philippines- Philippine General Hospital, Manila, Philippines


Background Systemic Lupus Erythematosus is an autoimmune disease, characterized as being in activity or remission. At present, various strategies and treatment options are well- recognized for improved patient management and disease control. Vaccination with the influenza and pneumococcal vaccines has been supported in studies worldwide. Despite this recommendation, several researches have documented the development of disease flares in patients with autoimmune diseases, and occurrence of a new autoimmune illness in previously healthy subjects, after vaccination.

Objectives To report on the experience of influenza and/ or pneumococcal vaccinations in Filipino SLE patients at the Philippine General Hospital

Methods The study was a descriptive study, collected retrospectively through chart reviews done at the Adult Rheumatology Clinic of the Philippine General Hospital. A total of 31 patients were included in the study. Records of the subjects were reviewed 8 weeks post- vaccination. Adverse reactions were noted. In addition, MEX-SLEDAI at baseline was compared to the score 8 weeks post- vaccination.

Results Thirty- one patients were included in this study. All patients were females. Approximately 80% reported no lupus activity at baseline. Most patients were on multiple drug therapy with low- dose prednisone and an anti- malarial. Eight out of 31 patients had fever, site irritation, and GI disturbance. Out of the 31 patients, 33% developed an increase in MEX- SLEDAI from baseline, with activity mostly comprising of cutaneous and nephritic manifestations. Non- compliance to medications and sun exposure were the factors identified in the development of the flares.

Conclusions Adverse reactions were noted in a small number of patients.Although 33% developed an increase in MEX- SLEDAI from baseline, these increases in baseline disease activity were noted to be multifactorial and could not be fully attributed to vaccination alone. However, despite such reactions and increases in MEX- SLEDAI, influenza and pneumococcal vaccination still appear to be well – tolerated among SLE patients.


  1. Barber C, Gold W, Fortin P. Infections in the lupus patient: Perspectives on prevention. Current Opinion in Rheumatology 2012; 51: 1061- 1069.

  2. Milanovic M, Stojanovich L, Djokovic A. Influenza vaccination in auroimmune rheumatic disease patients. Tohoku J Exp Med 2013; 229: 29- 34.

  3. Crowe S, Merill K, Vista E, Dedeke A, et al. Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.